Diabetic Retinopathy Market
The global diabetic retinopathy market is estimated to be valued at USD 9.30 Bn in 2024 and is expected to reach USD 14.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.3% from 2024 to 2031. Diabetic retinopathy is a medical condition in which damage occurs to the retina due to complications of diabetes mellitus. High blood sugar levels associated with diabetes can damage blood vessels inside the retina. Diabetic retinopathy occurs in both type 1 and type 2 diabetes and is a leading cause of blindness among working-age adults. The global diabetic retinopathy market is driven by rising prevalence of diabetes, increasing awareness regarding diabetic retinopathy diagnosis and treatment, and the availability of advanced retinal screening techniques. However, high cost of treatment and inadequate reimbursement policies limit the market growth.
Market Dynamics:
High cost of retinal screening, drugs, and surgeries, shortage of ophthalmologists in developing nations, and inadequate insurance coverage in some countries are expected to restrain the market growth. Key opportunity lies in development of cost-effective screening solutions, combinational therapeutics, and artificial intelligence-powered analytic platforms to detect diabetic retinopathy faster and more accurately.
Key Features of the Study:
- This report provides in-depth analysis of the global diabetic retinopathy market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031, considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetic retinopathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG, Bayer AG, Regeneron Pharmaceuticals Inc., Roche Holding AG, Allergan PLC, Zeiss International, Topcon Corporation, Heidelberg Engineering GmbH, Optos PLC, Canon Inc., Nidek Co., Ltd., Ellex Medical Lasers Limited, Bausch + Lomb Incorporated, Abbott Laboratories, and Santen Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diabetic retinopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Table of Contents
*Browse 32 market data tables and 28 figures on 'Diabetic Retinopathy Market' - Global forecast to 2032
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
